Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 11 Aug 2004 |
| Genmab, current statement of shareholdings | 11 Aug 2004 |
| Genmab, current statement of shareholdings | 5 Aug 2004 |
| Genmab, interim report - six months 2004 | 3 Aug 2004 |
| Genmab, Announces 2004 First Half Year Results | 3 Aug 2004 |